The risk of melanoma in patients with chronic lymphocytic leukemia; a population-based study.

[1]  C. Zent,et al.  Management of melanoma in patients with chronic lymphocytic leukemia. , 2018, Leukemia research.

[2]  J. E. Mayer,et al.  Inaccuracies in SEER registry data on melanoma thickness. , 2017, Journal of the American Academy of Dermatology.

[3]  Greta M. Massetti,et al.  Vital Signs: Melanoma Incidence and Mortality Trends and Projections — United States, 1982–2030 , 2015, MMWR. Morbidity and mortality weekly report.

[4]  J. Brewer,et al.  Melanoma in immunosuppressed patients. , 2012, Mayo Clinic proceedings.

[5]  A. Sevko,et al.  Melanoma-induced immunosuppression and its neutralization. , 2012, Seminars in cancer biology.

[6]  A. Weaver,et al.  Effects of Chronic Lymphocytic Leukemia on the Development and Progression of Malignant Melanoma , 2010, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[7]  S. Piaserico,et al.  Immunosuppression and melanocyte proliferation , 2009, Melanoma research.

[8]  Mauro Biffoni,et al.  The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. , 2008, Cancer research.

[9]  J. Hunter,et al.  Malignant melanoma and lymphoproliferative malignancy: is there a shared aetiology? , 2000, The British journal of dermatology.

[10]  S Hansen,et al.  Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. , 1999, Journal of the American Academy of Dermatology.

[11]  Josep Malvehy,et al.  Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. , 2010, European journal of cancer.

[12]  P. Boyle,et al.  Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. , 2005, European journal of cancer.

[13]  D. Federman,et al.  Skin Cancer and Non-Hodgkinʼs Lymphoma: Examining the Link , 2005 .